Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- olodaterol
- P6E1 (epinephrine / pilocarpine ophthalmic)
Interactions between your drugs
EPINEPHrine ophthalmic olodaterol
Applies to: P6E1 (epinephrine / pilocarpine ophthalmic), olodaterol
MONITOR: Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.
MANAGEMENT: Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.
References
- Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE (1990) "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet, 336, p. 1396-9
- (2002) "Product Information. Proventil (albuterol)." Schering Corporation
- "Product Information. Serevent (salmeterol)." Glaxo Wellcome
- (2001) "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals
- (2001) "Product Information. Xopenex (levalbuterol)." Sepracor Inc
- (2001) "Product Information. Foradil (formoterol)." Novartis Pharmaceuticals
- (2006) "Product Information. Brovana (arformoterol)." Sepracor Inc
- Lowe MD, Rowland E, Brown MJ, Grace AA (2001) "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart, 86, p. 45-51
- (2011) "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals
- (2013) "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline
- (2014) "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.